INFUNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
InfuSystem Holdings, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$13.74+0.34 (+2.54%)
Close on Oct 19, 2026
- Market cap
- $287.44M
- P/E (TTM)
- 33.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
56.0%−4.4 pts over 5 years
Operating margin
8.3%−0.8 pts over 5 years
Net margin
4.6%−13.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +6.4% | +9.3% | +8.1% | +7.4% | |
| Gross profit | +14.1% | +9.9% | +6.4% | +4.9% | |
| Operating income | +73.0% | +93.2% | +6.2% | +5.1% | |
| Net income | +182.6% | +616.7% | -17.5% | +9.1% | |
| EPS, diluted | +181.8% | – | -17.3% | +10.0% | |
| Free cash flow | +23.1% | +13.0% | +4.4% | +13.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -0.4% | 54.9% | 11.5% | |
| Return on assets | -0.2% | 19.7% | 6.5% | |
| Current ratio | 1.26 | 1.29 | 1.80 | |
| Debt to equity | 0.63 | 0.95 | 0.34 | |
| Net debt to EBITDA | – | 1.28× | 0.65× | |
| Interest coverage | 0.7× | 7.0× | 9.2× | |
| Inventory turnover | 12.6× | 13.1× | 10.6× | |
| Capex to revenue | 0.2% | 1.1% | 0.4% | |
| Diluted shares | 23M | 22M | 21M |
Where the cash went
Fiscal 2021 to 2025, five years combined
InfuSystem generated $91.92M from operations and spent $21.86M on capital expenditure, dividends and share buybacks. 21% of that went back into the business.
Generated
$91.92M
Used
$21.86M
Capital expenditure$4.64M21%Dividends$00%Share buybacks$17.22M79%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin4.6%
×Asset turnover1.41×
×Equity multiplier1.78×
=Return on equity, FY202511.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 4.6% | 1.41× | 1.78× | 11.5% |
| FY2024 | 1.7% | 1.31× | 1.88× | 4.3% |
| FY2023 | 0.7% | 1.24× | 2.02× | 1.7% |
| FY2022 | 0.0% | 1.12× | 2.05× | 0.0% |
| FY2021 | 1.4% | 1.05× | 2.19× | 3.2% |
| FY2020 | 17.8% | 1.11× | 2.79× | 54.9% |
| FY2019 | 1.7% | 1.13× | 3.35× | 6.4% |
| FY2018 | -1.6% | 1.01× | 2.59× | -4.3% |
| FY2017 | -29.1% | 0.86× | 2.02× | -50.7% |
| FY2016 | -0.3% | 0.74× | 1.90× | -0.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
8of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$6.63M
- Cash generatingOperating cash flow above zero$24.41M
- Return on assets improvedROA up on the prior year2.3% → 6.4%
- Earnings backed by cashOperating cash flow above net income$24.41M vs $6.63M
- Less leverageLong-term debt to assets fell23.0% → 19.5%
- Better liquidityCurrent ratio rose1.82 → 1.80
- No dilutionShare count did not rise22M → 21M
- Gross margin improvedGross margin up on the prior year52.20% → 55.98%
- More efficientAsset turnover rose1.31 → 1.38